Fresenius Kabi Files EU Pegfilgrastim

‘Milestone’ Biosimilar Submission Comes Ahead Of Planned Launch In 2021

 
• By David Wallace
  
Fresenius Kabi
Fresenius Kabi has seen its biosimilar pegfilgrastim filing accepted for EMA review • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products